Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 17/20 | 0.57 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.56 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.55 |
| ▸ | TUBB | P07437 | 1/20 | 0.55 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.55 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.55 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.55 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.55 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.55 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.55 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.55 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.55 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.55 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.55 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.55 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.55 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.55 |
| ▸ | MGAM | O43451 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | SI | P14410 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16345764 | 0.93 | ESR1 (0.60) | ESR1ESR2 | |
| SCHEMBL8377008 | 0.92 | TUBB4A (0.61) | ESR1ESR2TUBB4ATUBBTUBA3C | |
| SCHEMBL20425288 | 0.89 | ESR1 (0.56) | ESR1ESR2 | |
| SCHEMBL30610966 | 0.89 | ESR1 (0.56) | ESR1ESR2 | |
| SCHEMBL20442604 | 0.89 | ESR1 (0.71) | ESR1ESR2 | |
| SCHEMBL20442700 | 0.87 | ESR1 (0.59) | ESR1ESR2 | |
| SCHEMBL21906718 | 0.87 | ESR1 (0.59) | ESR1ESR2 | |
| SCHEMBL8467405 | 0.87 | TUBB4A (0.52) | ESR1ESR2TUBB4ATUBBTUBA3C | |
| SCHEMBL16346286 | 0.86 | ESR1 (0.63) | ESR1ESR2TUBB4ATUBBTUBA3C | |
| SCHEMBL16346487 | 0.86 | TUBB4A (0.70) | ESR1ESR2TUBB4ATUBBTUBA3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11384063-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20200199107-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. | 2020-06-25 | — | — | US | disclosed |
| US-10604506-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2020-03-31 | — | — | US | disclosed |
| WO-2018140809-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2018-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604506-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ADRM1, MDM2, ESR2 | ESR1 15/4885ESR2 3/4885TUBB4A 3970/4885 |
| US-11384063-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ADRM1, MDM2, ESR2 | ESR1 15/4885ESR2 3/4885TUBB4A 3970/4885 |
| US-20200199107-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ADRM1, MDM2, ESR2 | ESR1 15/4885ESR2 3/4885TUBB4A 3970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.